A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers

Falciparum Malaria Clinical Trial

Official title:
Phase Ib, Single-center, Randomized, Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers

Status Not yet recruiting

Clinical Trial Summary

Malaria is caused by protozoan parasites of the genus Plasmodium and it is the most important parasitic disease in terms of mortality and morbidity. Estimates of 247 million malaria cases and 619.000 deaths worldwide were reported by WHO for the year 2021 (1). Plasmodium falciparum can lead to severe malaria and accounts for 90% of malaria deaths that mainly occur in children below the age of 5 years in Sub-Saharan Africa. A simplified treatment regimen, ideally a single-day cure (or at most 2-day dosing regimen), of uncomplicated malaria due to P. falciparum would be the magic in the antimalarial armamentarium. Improving treatment adherence is one of the key factors in reducing mortality and morbidity and also the transmission of malaria, and such a regimen would substantially increase adherence. To find a new non-artemisinin combination therapy with a shorter regimen, ideally, a single-dose cure, with low resistance potential would be the aim. The two compounds tested here are ZY19489, a triaminopyrimidine, and ferroquine (FQ), a next-generation 4-aminoquinoline. Both compounds show unique features in terms of long half-life, and activity against current drug-resistant strains. Therefore, the main goal of this clinical trial is to assess the safety of the ZY19489-FQ combination given as a 1- or 2-day dose regimen.

Clinical Trial Description

Total of 36 participants (3 cohorts with up to 12 participants each).The participant will receive the intervention orally once daily for one or two days, following a fasting period of at least 10 hours.Total duration of trial participation for each participant: Approximately 10 weeks (screening visits + 64 days of follow-up). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05911828
Study type	Interventional
Source	Zydus Lifesciences Limited
Contact	Kevinkumar Kansagra, MD
Phone	02717-665555
Email	kevinkumarkansagra@zyduslife.com
Status	Not yet recruiting
Phase	Phase 1
Start date	August 1, 2024
Completion date	May 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00440752` - The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance	N/A
Completed	`NCT01144702` - Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum	Phase 2/Phase 3
Terminated	`NCT00400101` - Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides	Phase 1
Completed	`NCT01350856` - Tracking Resistance to Artemisinin (TRAC)	Phase 4
Completed	`NCT00859807` - A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects	Phase 4
Completed	`NCT04222088` - TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
Completed	`NCT01115439` - Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria	N/A
Completed	`NCT00282919` - A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria	Phase 2
Completed	`NCT04422015` - Biological Mechanisms in Afebrile P. Falciparum Malaria
Completed	`NCT00894660` - A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects	Phase 1
Completed	`NCT00894374` - Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects	Phase 1
Completed	`NCT00493363` - Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia	N/A
Completed	`NCT00158548` - ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan	Phase 3
Withdrawn	`NCT04289558` - Nitrite Infusion in Children With Malaria	Phase 1
Completed	`NCT01374126` - Azithromycin Combination Therapy for the Treatment of Severe Malaria	Phase 2
Completed	`NCT00722150` - Artemisinin Resistance in Cambodia II	N/A
Completed	`NCT00157833` - A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia.	N/A
Completed	`NCT00513669` - Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania	Phase 1
Completed	`NCT00442377` - Study to Investigate the Induction of an Protective Immune Response to Malaria	N/A
Completed	`NCT00403260` - Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.